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Abstract Mitochondrial microsatellite instability (mtMSI), a
change in length in mtDNA microsatellite sequences between
normal and tumor tissue, has been described as a frequent
occurrence in colorectal cancer (CRC).We evaluated the prev-
alence and prognostic value of mtMSI and its relation to nu-
clear microsatellite instability (MSI) in patients with metasta-
tic CRC (mCRC). At six loci (D310, D514, D16184, ND1,
ND5, and COX1), the mitochondrial DNA sequence was an-
alyzed in normal and tumor tissue, and the mtMSI status was
determined. We evaluated the prevalence and outcome in
terms of overall survival (OS) in 83 CRC patients with a
MSI tumor (including 39 patients with Lynch syndrome)
and in 99 mCRC patients with a microsatellite stable (MSS)
tumor. A meta-analysis was performed to compare our find-
ings with existing data. mtMSI at the D-loop region was found
in 54.4 % (99 out of 182) of all patients. Prevalence of mtMSI
was most pronounced at the D310 locus (50.5 %). Prevalence
of mtMSI at the D-loop region was not different among pa-
tients withMSI compared toMSS tumors. There was no effect
of mtMSI on prognosis in patients with MSI or MSS tumors.
Prevalence of mtMSI was high in mCRC patients with both
MSI and MSS tumors, but there was no correlation with prog-
nosis. mtMSI was particularly present at the D310 locus.
Keywords Metastatic colorectal cancer . mtMSI
Introduction
Colorectal cancer (CRC) carcinogenesis is a multistep process
involving the accumulation of genetic changes. CRC research
is largely focused at activation of oncogenes, inactivation of
tumor suppressor genes, and defects of mismatch repair genes
in nuclear DNA. However, there are still many aspects that
cannot be explained by these genetic changes.
More than half a century ago, OttoWarburg was the first to
describe that mitochondria may play a role in carcinogenesis
[47]. A mitochondrion is a membrane-enclosed intracellular
organelle present in many copies per cell, which contains its
own genetic system for replication, transcription, and transla-
tion [44]. Mitochondria generate most of the cell’s supply of
adenosine triphosphate (ATP), the major energy source of the
cell, and are therefore involved in cell signaling, cellular dif-
ferentiation, apoptosis, and control of the cell cycle and cell
growth.
The mitochondrial DNA is a 16,569-base pairs, double-
stranded, circular DNA composed of genes and a noncoding
region, the displacement loop (D-loop), which contains essen-
tial transcription and replication elements [30, 45]. The genes
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encode for both a small (12S) and a large (16S) ribosomal
RNA gene, 22 transfer RNAs and 13 proteins.
The genetics of mitochondria differ from genetics of
the nuclear genome in 3 major characteristics: maternal
inheritance, heteroplasmy, and mitotic segregation [8].
Initially, it was assumed that mitochondrial DNA is
homoplasmic in normal cells, that is, all of the mito-
chondrial DNA copies are identical not only in an indi-
vidual cell but also among cells. However, new se-
quencing techniques revealed that heteroplasmy is not
restricted to cancer cells but can also be present in
normal tissue [15].
It has been reported that mitochondrial DNA is more
susceptible to mutations than nuclear DNA, due to the
lack of histones and chromatin structure, paucity of in-
trons, inefficient mitochondrial DNA repair mechanisms
and a higher exposure to reactive oxygen species (ROS)
produced by ATP synthesis [33, 41]. Several hotspots of
mitochondrial DNA mutations have been described in
tumor tissue. A major target was found at the D310
sequence (CnTC6) in the non-coding D-loop [37]. In
CRC, somatic mutations were also found at the D514
and D16184 sequence in the non-coding D-loop, rRNA
genes, NADH dehydrogenase subunits (ND1, ND4L,
and ND5), cytochrome b, and cytochrome oxidase sub-
units (COX1, COX2, and COX3). The majority of mu-
tations were nucleotide substitutions or single base pair
insertions. However, only few studies have sequenced
the entire mitochondrial genome [15, 23]; most studies
focused only on a few regions or exclusively at the D-
loop region in CRC [1, 2, 9, 16, 17, 19, 40, 46]. Data
about mitochondrial DNA mutations are therefore scarce
and inconsistent.
Mitochondrial microsatellite instability (mtMSI) has
been defined as change in length in short base repetitive
sequences of mitochondrial DNA (mtDNA) between
normal and tumor tissue. mtMSI has been described as
a frequent occurrence in human cancers [4, 5] and also
in CRC [12, 14, 35]. Several studies have evaluated the
relation of nuclear MSI with mtMSI, but results are
inconclusive. The association between mtMSI and other
clinical factors was also analyzed. In stage III CRC
cancers, the presence of mtMSI at the D-loop is associ-
ated with poor prognosis and resistance to fluorouracil-
based adjuvant chemotherapy [27].
To date, no data are available regarding the prevalence
or prognostic value of mtMSI in metastatic CRC (mCRC)
patients. We hypothesize that the presence of mtMSI
might confer a worse prognosis in mCRC, as seen in
stage III CRC. We therefore assessed the role of mtMSI
in respect to prevalence and outcome in patients with
mCRC with either MSI or microsatellite stable (MSS)
tumors.
Materials and methods
Clinical samples
Data were derived from mCRC patients included in two large
phase III studies: CAIRO (Clinicaltrials.gov NCT00312000)
and CAIRO2 (Clinicaltrials.govNCT00208546), of which the
results have been published previously [21, 42]. Collection of
formalin-fixed paraffin-embedded (FFPE) material of the pri-
mary tumor was part of the initial protocol in both studies. To
check that the normal colon tissue of CRC patients has a
constant sequence pattern, we selected 10 patients from our
hospital database for which we could obtain normal tissue
from proximal and distal locations relative to the tumor.
In order to analyze the prevalence and relation between
nuclear MSI and mtMSI, we selected 44 mCRC patients with
MSI tumors from the CAIRO studies (CAIRO [22], n=19,
and CAIRO2 [42], n=25) and 39 CRC patients with a known
Lynch syndrome from our own database. Furthermore, we
selected 56 mCRC patients with MSS tumors treated in the
CAIRO study who were matched for known prognostic fac-
tors (the ‘test group’); all patients that were treated with first-
line capecitabine monotherapy for at least 3 cycles had a re-
section of the primary tumor, WHO performance score 0,
normal serum lactate dehydrogenase (LDH) concentrations,
localization of the primary tumor in colon or rectosigmoid
and had not received prior adjuvant chemotherapy. In order
to validate the results found in the test group, we randomly
selected 43 patients with MSS tumors treated in the CAIRO
study as a validation group.
Mitochondrial microsatellite instability (mtMSI) analysis
Genomic DNA was extracted from four to eight manually
microdissected 30-μm sections of FFPE tissue. Areas contain-
ing >50 % tumor cells were selected by microscopic evalua-
tion on a reference slide stained with H&E. Genomic DNA
DNA micro kit (Qiagen, Valencia, CA) following the manu-
facturer’s instructions. DNA concentration was determined at
260 nm using the Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies, Inc., Wilmington, DE, USA). The
sequence of mutational hotspot regions was determined by
PCR and Sanger sequencing using six primer sets: D-loop
310 (C8TC6), D-loop 514 (CA5), D-loop 16184 (C12), ND1
(C6), ND5 (C6A8), and COX1 (A7) (Supplemental Table 1)
[10, 25, 28, 43]. The fragments were analyzed for length var-
iations in tumor tissue compared to normal tissue (instability).
We read the electropherograms manually to identify variable
sequence length present at low level and to determine if there
was coexistence of different subpopulations of the mononu-
cleotide tracts in tumor tissue and normal tissue
(heteroplasmy). Heteroplasmy makes analysis with
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from microdissected tissues was isolated using the QIAamp®
GeneScan, which is used for nuclear MSI, difficult. Some
samples revealed a different proportion of mtDNA subpopu-
lation between normal and tumor tissue. Such a difference can
occur due to changes in the proportion of mtDNA subpopu-
lations during mitochondrial segregation or due to mutations,
and we also classified these as instable. The analyses were
performed in duplicate on normal and tumor DNA of the
selected patients. The results were independently scored by
two observers. In case of inconsistent results, the entire mtMSI
experiment was repeated, and the final conclusion was based
on two similar results. Due to technical failure, only 152 in-
stead of 182 patients were analyzed for ND5.
Statistical analysis
Patients were analyzed for the prevalence and prognostic val-
ue in four different groups: patients with combined MSI and
mtMSI tumors (MSI/mtMSI), patients with combined MSI
and mtMSS tumors (MSI/mtMSS), patients with combined
MMS and mtMSI tumors (MSS/mtMSI), and patients with
combinedMSS andmtMSS tumors (MSS/mtMSS). The prev-
alence of mtMSI was compared for patients with MSI and
MSS tumors. The outcome was analyzed within the group
of patients with MSI tumors (excluding the Lynch syndrome
patients) for mtMSI compared to mtMSS tumors and within
the group of patients with MSS tumors for mtMSI compared
to mtMSS tumors.
For the mtMSI analysis of the D-loop region (D310 locus,
D514 locus, and D16184 locus) and per loci, patients were
divided into two groups: stable versus instable tumors. The
comparison of the prevalence of mtMSI between groups (MSI
versus MSS) was performed by chi-square or Fisher’s exact
tests, where appropriate. OS was defined as the time from ran-
domization until death from any cause. OS curves were esti-
mated using the Kaplan–Meier method and compared using a
Cox proportional hazard model. All tests were two-sided, and
p<0.05 was considered as statistically significant. All analyses
were conducted using the SAS system version 9.2.
Literature search strategy, inclusion criteria, and data
extraction
We reviewed the literature on the prevalence of mtMSI in
stage I–IV CRC patients. The primary outcome of interest
was prevalence of mtMSI. A search was conducted of
Medline, PubMed, and the Cochrane Library from January
1998 (year of the first publication of mtMSI in CRC) to Jan-
uary 2014 with an English-language restriction using the fol-
lowing search terms: mitochondrial microsatellite instability,
mitochondrial mutations, and mitochondrial alterations, in
combination with colon cancer and colorectal cancer. Original
publications were selected if the abstract contained data for
patients with mtMSI. In case of duplicate publications, the
most recent and/or most complete study was included. We
excluded publications of patients with colon cancer and
CRC in which only mutations in the mitochondrial genome
were described.
Results
Prevalence of mtMSI at the D-loop
mtMSI has been defined as change in length in short base
repetitive sequences of mtDNA between normal and tumor
tissue. This assumes that the normal colon tissue of CRC
patients has a constant sequence pattern. This was checked
for the D310 and D514 region in 10 patients from our hospital
database for which we could obtain normal tissue from prox-
imal and distal locations relative to the tumor.We analyzed the
mtDNA with PCR and Sanger sequencing. In these 10 pa-
tients, we did not observe a difference in the normal tissues,
but in five patients, the tumor did show an altered fragment
length at the D310 region (Supplementary Table 2). This re-
sult confirms that mtMSI is a tumor-specific event and that the
comparison of one tumor and one normal tissue block per
patient should be sufficient to assess mtMSI. Figure 1 illus-
trates an example of mtMSI analyzed by direct sequencing.
Analyses were done in duplicate. Overall, 54.4 % (99 out of
182) of all patients showedmtMSI at the D-loop region (D310
locus+D514 locus+D16184 locus). The majority of all pa-
tients showed mtMSI at the D310 locus (50.5 %), whereas
instability at the D514 locus was found in 4.9 % of all patients
and instability at the D18164 locus in 1.6 % of all patients
(Fig. 2). mtMSI at the D-loop region was most often found at
only one of the three D-loop loci (94 out of 99). Five patients
showed instability at two loci, with the following combina-
tions: D310 and D514 (n=2), D310 and D16184 (n=2), and
D514 and D16184 (n=1). Patients with MSI tumors showed
slightly more often mtMSI at the D-loop region compared to
patients with MSS tumors; 57.8 versus 51.5 %, p=0.083.
Prevalence of mtMSI at ND1, ND5, and COX1
Instability at the NADH dehydrogenase subunits ND1 and
ND5 was rare. Only 1.1 % of patients (2 out of 182) showed
instability at the ND1 locus, and 4.6 % (7 out of 153) of
patients showed instability at the ND5 locus. None of the
patients showed instability at the cytochrome oxidase subunit
COX1.
Prognosis of mtMSI at the D-loop region
Baseline patient and tumor characteristics of all patients are
summarized in Table 1. Survival data for mtMSI at the D-loop
region (D310 locus+D514 locus+D16184 locus) are
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presented in Table 2. There was no correlation of OS with
mtMSI at the D-loop region, when analyzing the three D-
loop loci separately or together.
Review of the literature
The literature search identified 10 retrospective, non-random-
ized, single center studies in stage I–IV CRC (Fig. 3) [6, 11,
12, 24, 26–28, 34, 39, 43]. All studies analyzed the same loci
and the same repeat; however, the definition of mtMSI was
different among studies. Some studies used the same def-
inition of mtMSI as we used in the current study [11, 12,
28, 39, 43]. While other studies describe insertion and
deletions of C nucleotides in the mononucleotide repeat
as mutations or alterations [6, 24, 26, 27, 34]. Two studies
used band-shifting [12, 39], while all the other studies
A B 
Fig. 1 Electropherograms obtained by direct sequencing of the mitochondrial D310 region of matched normal (a) and tumor (b) tissue. The (C)n status
of the major population differ in the samples. a C6TC8 and b C6TC7. This is an example of mtMSI
C 
A B 
Stable (n=90) Instable (n=92)
Stable (n=179) Instable (n=3)
Instable (n=9)Stable (n=173)
Fig. 2 Prevalence of mtMSI at the D310 locus (50.5 %) (a), at the D514 locus (4.9 %) (b), and at the D18164 locus (1.6 %) (c) of all patients
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Table 1 Baseline patient and
tumor characteristics of all
patients treated in the CAIRO
studies, subdivided by patients
with MSI and MSS tumors
MSI microsatellite instability,
MSS microsatellite stable
Patients with MSI tumors Patients with MSS tumors
Test group Validation group
(n=44) (n=56) (n=43)
Median age (range) 68 (34–78) 66 (34–79) 68 (39–81)
Sex
Male 24 (55 %) 37 (66 %) 28 (65 %)
Female 20 (45 %) 19 (34 %) 15 (35 %)
WHO performance status
PS0 28 (64 %) 56 (100 %) 26 (61 %)
PS1 14 (32 %) – 16 (37 %)
PS2 2 (4 %) – 1 (2 %)
Serum LDH
Normal 32 (73 %) 56 (100 %) 29 (67 %)
Abnormal 12 (27 %) – 14 (33 %)
Localization of the primary tumor
Colon 38 (86 %) 48 (86 %) 26 (61 %)
Recto sigmoid 2 (4 %) 8 (14 %) 1 (2 %)
Rectum 3 (7 %) – 15 (35 %)
Multiple tumor 1 (3 %) – 1 (2 %)
Metastatic sites involved
Median 2 2 1
1 16 (36 %) 26 (46 %) 22 (51 %)
>2 26 (60 %) 30 (54 %) 21 (49 %)
unknown 2 (4 %) – –
Predominant localization of metastases –
Liver 14 (32 %) 40 (71 %) 27 (63 %)
Liver+other 13 (30 %) – –
Extra-hepatic 16 (36 %) 15 (27 %) 16 (37 %)
Unknown 1 (2 %) 1 (2 %) –
Histology of the primary tumor
Mucinous (>50 % WHO) 16 (36 %) 5 (9 %) 4 (9 %)
Adenocarcinoma with mucinous component 4 (9 %) 6 (11 %) 4 (9 %)
Adenocarcinoma 23 (52 %) 41 (73 %) 34 (80 %)
Unknown 1 (3 %) 4 (7 %) 1 (2 %)
Table 2 Survival data of the
patients with MSI and MSS
tumors in relation to the mtMSI
status of the D-loop region (D310
locus+D514 locus+D16184
locus)
OS overall survival, HR hazard
ratio
D-loop region
mtMSS mtMSI
MSI tumors Number of patients 17 27
OS Months (95 % CI) 16.2 (8.5–19.8) 13.1 (7.3–19.8)
HR (95 % CI) 0.96 (0.50–1.84)
Test group
(MSS tumors)
Number of patients 30 26
OS Months (95 % CI) 19.1 (17.1–28.6) 20.1 (13.6–26.2)
HR (95 % CI) 1.20 (0.67–2.12)
Validation group
(MSS tumors)
Number of patients 18 25
OS Months (95 % CI) 16.3 (12.5–27.3) 18.3 (12.9–21.0)
HR (95 % CI) 1.23 (0.64–2.35)
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used direct sequencing to detect mtMSI. All studies eval-
uated the D310 locus separately. Prevalence of mtMSI at
the D310 locus ranged from 24.1 to 44.4 % (Fig. 3). Only
one study evaluated the prevalence at other regions (D514
and D16184) of the D-loop, and they found mtMSI at the
D16184 locus in 18.6 % of patient and at the D514 locus
in 7.4 % of patients [28]. Prevalence of mtMSI at the
ND1 and ND5 locus was low and ranged from 1.2 to
6.8 % [12, 34, 43]. In Fig. 4, the different studies com-
paring the prevalence of mtMSI in stage I–IV CRC pa-
tients with MSI and MSS tumors are summarized in a
forest plot [11, 27, 34, 39, 43]. mtMSI was not signifi-
cantly more frequent in tumors with MSI (RR 1.07, 95 %
CI 0.88–1.30).
Discussion
In the current study, we demonstrate a high prevalence of mtMSI
in mCRC patients with both MSI and MSS tumors. mtMSI was
particularly present at the D310 locus. There was no correlation
with prognosis. The D-loop is a triple stranded structure, and its
attachment to the nuclear membrane with the subsequent
exposure to lipid peroxides formed in the inner mitochondrial
membrane makes this region prone for mutations in cancer cells
(in particular the D310 region [29]). It is the most variable region
in mtDNA and alterations, such as point mutations, insertions,
deletions, andmtMSI are common events [3]. This is in line with
the high prevalence of instability found at the D310 locus in the
current study and previous published studies in stage I–IV CRC
(Fig. 2a) [6, 11, 12, 24, 26–28, 34, 39, 43]. In our study, the
prevalence of instability at the D-loop (and the D310 locus) is
even higher compared to previous published studies [19, 24,
26–33]. The high prevalence might be caused by our selection
of patients with metastatic disease, since some studies demon-
strated a link between mtMSI with poor prognosis [27] and ad-
vanced stage of disease [18, 20]. Alternatively, the variation of
prevalence of instability at the D-loop might be caused by differ-
ences in the applied definitions and diagnostic panels. There are
multiple potential pitfalls in the detection methodology [36]. Di-
rect sequencing has a limited detection level and is hardly quan-
titative. The heteroplasmymakes it hard to determine whether an
alteration results from genuinemutation or simply reflects chang-
es in the proportion of mtDNA subpopulations duringmitochon-
drial segregation. For future research, next generation sequencing
and analyses of larger cohorts will be useful. Instability at the
ND1 and ND5 genes, subunits of the NADH dehydrogenase
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complex, is rare in CRC [12, 43] and only occurs in combination
with instability at the D310 locus. This suggests that these might
be secondary effects, similar to those observed in nuclear MSI
[31].
The current study and previous studies on the correlation
between nuclear MSI and mtMSI in CRC showed that nuclear
MSI and mtMSI are independent events, suggesting that MMR
enzymes are not involved in the correction of mtDNA base
mispairing [11, 27, 34, 39, 43]. This is consistent with the fact
that nuclear MMR proteins do not have any mitochondrial local-
ization signal and cannot be detected in mitochondria by immu-
nohistochemical analysis [13]. Furthermore, it was shown that in
mitochondria, YB-1 mediates strong MMR activity, which is
unrelated to nuclear MMR proteins [7, 32]. Important questions
that still remain unanswered are the following: what are the func-
tional consequences of mtMSI, is mtMSI a cause or a conse-
quence of tumorigenesis, and especially, does mtMSI have prog-
nostic value? The D-loop region is a crucial site for replication
and expression of the mitochondrial genome because it contains
essential transcription and replication elements [30, 45]. For that
reason, one may speculate that sequence variations in this region
can alter mtDNA replication and transcription and thus mito-
chondrial function. Then again, most of the variations are in the
polymorphic length range and thus unlikely to lead to functional
impairment of the mitochondria [38]. The prognostic value of
mtMSI was only analyzed in four other studies in stage I–IV
CRC patients, and results were inconsistent [6, 11, 27, 43].
One study found an association between alteration in the D-
loop and poor prognosis in stage III CRCpatients [27]. However,
this was not confirmed in a subsequent study [43]. Also, in our
study, there was no correlation with prognosis. Taken together,
mtMSI at the D310 locus is frequent in CRC patients, but the
prognostic value is still unclear.
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